Chemotherapy options and new advances in malignant pleural mesothelioma

Annals of Oncology

Volumn 16, Issue 3, 2005, Pages 345-351

  Steele, Jeremy P C ^a   Klabatsa, A ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Cancer; Chemotherapy; Mesothelioma; Novel agents

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ASBESTOS; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EDATREXATE; EPIRUBICIN; FLUOROURACIL; FOLATE RECEPTOR; FOLIC ACID ANTAGONIST; FOLINIC ACID; GAMMA INTERFERON; GEMCITABINE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; TAXANE DERIVATIVE; TEMOZOLOMIDE; UNINDEXED DRUG; VINCA ALKALOID;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG FATALITY; DRUG RESPONSE; DRUG TARGETING; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PERCEPTION; PLEURA FLUID; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; GLUTAMATES; GUANINE; HUMANS; MESOTHELIOMA; PALLIATIVE CARE; PLEURAL NEOPLASMS; PROGNOSIS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; THIOPHENES;

EID: 16244362744     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi094     Document Type: Review

References (74)

1. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma: A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991; 102: 1-9.
2. Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of a 5-yr experience, with special reference to radiotherapy. Am J Clin Oncol 1990; 13: 4-9.
3. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997; 145: 211-218.
4. Peto J, Decarli A, la Vecchia C et al. The European mesothelioma epidemic. Br J Cancer 1999; 79: 666-672.
5. International Ban Asbestos Secretariat website. http://www.btinternet.com/~ibas/ (date last accessed August 2004).
6. Chahinian AP, Pajak TF, Holland JF et al. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med 1982; 96: 746-755.
7. Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 2000; 44: 565-601.
8. Rees D, Goodman K, Fourie E et al. Asbestos exposure and mesothelioma in South Africa. S Afr Med J 1999; 89: 627-634.
9. Boutin C, Dumortier P, Rey F et al. Black spots concentrate oncogenic asbestos fibers in the parietal pleura. Thoracoscopic and mineralogic study. Am J Respir Crit Care Med 1996; 153: 444-449.
10. Bianchi C, Giarelli L, Grandi G et al. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev 1997; 6: 162-166.
11. Bocchetta M, Di Resta I, Powers A et al. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci USA 2000; 97: 10214-10219.
12. Procopio A, Strizzi L, Vianale G et al. Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes Cancer 2000; 29: 173-179.
13. ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 2001; 18: 425-433.
14. Fennell DA, Rudd RM. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 2004; 5: 354-362.
15. International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995; 108: 1122-1128.
16. Herndon JE, Green MR, Chahinian AP et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113: 723-731.
17. Curran D, Sahmoud T, Therasse P et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16: 145-152.
18. Steele JP. Prognostic factors in mesothelioma. Semin Oncol 2002; 29: 36-40.
19. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
20. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15: 257-260.
21. Lerner HJ, Schoenfeld DA, Martin A et al. Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983; 52: 1981-1985.
22. Magri MD, Veronesi A, Foladore S et al. Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. Tumori 1991; 77: 49-51.
23. Baas P. Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin Oncol 2002; 29: 62-69.
24. Steele JP, O'Doherty CA, Shamash J et al. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann Oncol 2001; 12: 497-499.
25. Zidar BL, Green S, Pierce HI et al. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest New Drugs 1988; 6: 223-226.
26. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
27. van Meerbeeck JP, Manegold C, Gaafar R et al. A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC. Proc Am Soc Clin Oncol 2004; (Abstr 7021).
28. Planting AST, Schellens JHM, Goey SH et al. Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol 1994; 5: 373-374.
29. Vogelzang NJ, Goutsou M, Corson JM et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990; 27: 239-242.
30. Raghavan D, Gianoutsos P, Bishop J et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990; 8: 151-154.
31. Bueno R, Appasani K, Mercer H et al. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 121: 225-233.
32. Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992; 65: 956-960.
33. Kindler HL, Belani CP, Herndon JE II et al. Edatrexate (10-ethyldeaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the Cancer and Leukemia Group B. Cancer 1999; 86: 1985-1991.
34. Fizazi K, Caliandro R, Soulié P et al. Combination raltitrexed (Tomudex®)-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer 2000; 36: 1514-1521.
35. Harvey VJ, Slevin ML, Ponder BAJ et al. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 1984; 54: 961-964.
36. Otterson GA, Herndon JE 2nd, Watson D et al. Cancer and Leukemia Group B. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer 2004; 44: 251-259.
37. Steele JP, Shamash J, Evans MT et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18: 3912-3917.
38. Kindler HL, Van Meerbeeck JP. The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol 2002; 29: 70-76.
39. Tomek S, Emri S, Krejcy K, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer 2003; 27: 167-174.
40. Bajorin D, Kelsen D, Mintzer DM. Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 1987; 71: 857-858.
41. Sörensen PG, Bach F, Bork E, Hansen HH. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 1985; 69: 1431-1432.
42. Van Meerbeeck JP, Baas P, Debruyne C et al. A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. Eur J Cancer 2002; 38: 779-783.
43. Fizazi K, Doubre H, le Chevalier T et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 2003; 21: 349-354.
44. Schutte W, Blankenburg T, Lauerwald K et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 2003; 4: 294-297.
45. Steele JP, Shamash J, Evans MT et al. Phase II trial of vinorelbine and oxaliplatin (VO) in malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol 2001; 20: 335a (Abstr 1335).
46. Byrne MJ, Davidson JA, Musk AW et al. Cisplatin and gemcitabine treatment for malignant pleural mesothelioma: a phase II study. J Clin Oncol 1999; 17: 25-30.
47. Van Haarst JMW, Baas P, Manegold C et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002; 86: 342-345.
48. Clinical Trials PDQ®. Available at: http://www.clinicaltrials.gov/ (date last accessed February 2004).
49. Knuuttila A, Ollikainen T, Halme M et al. Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma - a feasibility study. Anti-Cancer Drugs 2000; 11: 257-261.
50. Nakano T, Chahinian AP, Shinjo M et al. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 1999; 85: 2375-2384.
51. Steele JP, Shamash J, Barlow CS et al. Phase II trial of irinotecan, cisplatin and mitomycin C (IPM) in malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol 2002; 21: 307a (Abstr 1227).
52. Halme M, Knuuttila A, Vehmas T et al. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer 1999; 80: 1781-1785.
53. Antman K, Pass H, Schiff P. Management of mesothelioma. In DeVita, Hellman, Rosenberg (eds): Cancer: Principles and Practice of Oncology, 6th edition. Philadelphia, PA: Lippincott, Williams & Wilkins 2001; 1943-1970.
54. Middleton GW, Smith IE, O'Brien ME et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998; 9: 269-273.
55. Muers MF, Rudd RM, O'Brien ME et al. British Thoracic Society Mesothelioma Group. BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax 2004; 59: 144-148.
56. Curtin NJ, Hughes AN. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol 2001; 2: 298-306.
57. Takimoto CH, Baker SD, Sweeney CJ et al. Phase I and pharmacokinetic study of pemetrexed disodium (LY231514, MTA, Alimta) in patients (pts) with impaired renal function. Proc Am Soc Clin Oncol 2001; 20: 93a (Abstr 368).
58. 12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21: 1556-1561.
59. Steele JP. The new front line treatment for malignant pleural mesothelioma? Thorax 2003; 58: 96-97.
60. Mikulski SM, Costanzi JJ, Vogelzang NJ et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002; 20: 274-281.
61. Vogelzang N, Taub R, Shin D et al. Phase III randomized trial of onconase (ONC) vs. doxorubicin (DOX) in patients (pts) with unresectable malignant mesothelioma (UMM): analysis of survival. Proc Am Soc Clin Oncol 2000; 19: 557a (Abstr 2274).
62. Astoul P, Viallat J-R, Laurent JC et al. Intrapleural recombinant IL-2 in passive immumotherapy for malignant pleural effusion. Chest 1993; 103: 209-213.
63. Astoul P, Picat-Joossen D, Viallat JR, Boutin C. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 1999; 83: 2099-2104.
64. Parra HS, Tixi L, Latteri F et al. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma. a phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer 2001; 92: 650-656.
65. Govindan R, Kratzke RA, Herndon JE et al. Gefitinib in patients with malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30101). Proc Am Soc Clin Oncol 2003; 22: 630 (Abstr 2535).
66. Millward M, Parnis F, Byrne M et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc Am Soc Clin Oncol 2003; 22: 228 (Abstr 912).
67. Imperiale MJ, Pass HI, Sanda MG. Prospects for an SV40 vaccine. Semin Cancer Biol 2001; 11: 81-85.
68. Hassan R, Lerner MR, Benbrook D et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res 2002; 8: 3520-3526.
69. Masood R, Kundra A, Zhu S et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 2003; 104: 603-610.
70. Nowak AK, Lake RA, Kindler HL, Robinson BWS. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 2002; 29: 82-96.
71. Kindler HL. Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer 2004; 45 (Suppl 1): S125-S127.
72. Kindler HL, Vogelzang NJ, Chien K et al. SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study. Proc Am Soc Clin Oncol 2001; 20: 341a (Abstr 1359).
73. Samson MK, Wasser LP, Borden EC et al. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol 1987; 5: 86-91.
74. Ardizzoni A, Rosso R, Salvati F et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 1991; 67: 2984-2987.